publication . Article . 2013

Effects of baseline CSF α-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease.

Niklas Mattsson; Philip Insel; Duygu Tosun; Jing Zhang; Clifford R Jack; Douglas Galasko; Michael Weiner; Alzheimer’s Disease Neuroimaging Initiative;
Open Access
  • Published: 01 Jan 2013
  • Publisher: eScholarship, University of California
  • Country: Mexico
Abstract
Background: Cerebrospinal fluid (CSF) α-synuclein is reduced in synucleinopathies, including dementia with Lewy bodies, and some studies have found increased CSF α-synuclein in Alzheimer's disease (AD). No study has explored effects of CSF α-synuclein on brain atrophy. Here we tested if baseline CSF α-synuclein affects brain atrophy rates and if these effects vary across brain regions, and across the cognitive spectrum from healthy elders (NL), to patients with mild cognitive impairment (MCI) and AD. Methods: Baseline CSF α-synuclein measurements and longitudinal structural brain magnetic resonance imaging was performed in 74 NL, 118 MCI patients and 55 AD patie...
Subjects
Medical Subject Headings: nervous system diseasesmental disordersnervous system
free text keywords: Alzheimer’s Disease Neuroimaging Initiative, Brain, Humans, Alzheimer Disease, Atrophy, Organ Size, Case-Control Studies, Aged, 80 and over, Middle Aged, Female, Male, alpha-Synuclein, Cognitive Dysfunction, and over, Brain Disorders, Clinical Research, Parkinson's Disease, Neurodegenerative, Alzheimer's Disease including Alzheimer's Disease Related Dementias, Alzheimer's Disease, Aging, Dementia, Acquired Cognitive Impairment, Neurosciences, 2.1 Biological and endogenous factors, Neurological, General Science & Technology, Medicine, R, Science, Q, Research Article
Funded by
NIH| Brain Aging and Alzheimer's Biomarker Classification Using Amyloid PET, tau PET, and Neurodegeneration on MRI: Developing the ATN system
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 2R01AG041851-06
  • Funding stream: NATIONAL INSTITUTE ON AGING
,
NIH| Large Scale Biomarker Discovery and Validation for Parkinsons Disease
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1U01NS082137-01
  • Funding stream: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
,
NIH| Stroke and Cognitive Impairment in Aging Chronic Kidney Disease Patients
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5R01AG037551-03
  • Funding stream: NATIONAL INSTITUTE ON AGING
,
NIH| "MR Morphometrics and Cognitive Decline Rate in Large-Scale Aging Studies"
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5K01AG030514-02
  • Funding stream: NATIONAL INSTITUTE ON AGING
,
NIH| Pacific Northwest Udall Center
Project
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1P50NS062684-01A1
  • Funding stream: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
Communities
Neuroinformatics
27 references, page 1 of 2

1 Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF et al. (2008) Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18625222.

2 Ohrfelt A, Grognet P, Andreasen N, Wallin A, Vanmechelen E et al. (2009) Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett 450: 332–335. doi:10.1016/j.neulet.2008.11.015. PubMed: 19022350.19022350 [OpenAIRE] [PubMed] [DOI]

3 Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M et al. (2006) Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. Biochem Biophys Res Commun 349: 162–166. doi:10.1016/j.bbrc.2006.08.024. PubMed: 16930553.16930553 [OpenAIRE] [PubMed] [DOI]

4 Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF et al. (2011) Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 69: 570–580. doi:10.1002/ana.22311. PubMed: 21400565.21400565 [OpenAIRE] [PubMed] [DOI]

5 Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev Neurol 6: 131–144. doi:10.1038/nrneurol.2010.4. [OpenAIRE] [DOI]

6 Hamilton RL (2000) Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol Zurich Switz 10: 378–384.

7 Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ (1999) Antibodies to alpha-synuclein detect Lewy bodies in many Down’s syndrome brains with Alzheimer’s disease. Ann Neurol 45: 353–357. doi:10.1002/1531-8249(199903)45:3. PubMed: 10072050.10072050 [PubMed] [DOI]

8 Arai Y, Yamazaki M, Mori O, Muramatsu H, Asano G et al. (2001) Alpha-synuclein-positive structures in cases with sporadic Alzheimer’s disease: morphology and its relationship to tau aggregation. Brain Res 888: 287–296. doi:10.1016/S0006-8993(00)03082-1. PubMed: 11150486.11150486 [PubMed] [DOI]

9 Reesink FE, Lemstra AW, van Dijk KD, Berendse HW, van de Berg WDJ et al. (2010) CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer’s disease. J Alzheimers Dis JAD 22: 87–95. doi:10.3233/JAD-2010-100186.20847452 [OpenAIRE] [PubMed] [DOI]

10 Tateno F, Sakakibara R, Kawai T, Kishi M, Murano T (2012) Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis Assoc Disord 26: 213–216. doi:10.1097/WAD.0b013e31823899cc. PubMed: 22037599.22037599 [PubMed] [DOI]

11 Wennström M, Surova Y, Hall S, Nilsson C, Minthon L et al. (2013) Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLOS ONE 8: e53250. doi:10.1371/journal.pone.0053250. PubMed: 23308173.23308173 [OpenAIRE] [PubMed] [DOI]

12 Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y et al. (2012) Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 69: 1445–1452. doi:10.1001/archneurol.2012.1654. PubMed: 22925882.22925882 [OpenAIRE] [PubMed] [DOI]

13 Korff A, Liu C, Ginghina C, Shi M, Zhang J (2013) α-Synuclein in Cerebrospinal Fluid of Alzheimer’s Disease and Mild Cognitive Impairment. J Alzheimers Dis JAD. doi:10.3233/JAD-130458. [OpenAIRE] [DOI]

14 Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J (2013) CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease. Acta Neuropathol (Berl). doi:10.1007/s00401-013-1148-z. [OpenAIRE] [DOI]

15 Olichney JM, Galasko D, Salmon DP, Hofstetter CR, Hansen LA et al. (1998) Cognitive decline is faster in Lewy body variant than in Alzheimer’s disease. Neurology 51: 351–357. doi:10.1212/WNL.51.2.351. PubMed: 9710002.9710002 [OpenAIRE] [PubMed] [DOI]

27 references, page 1 of 2
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue